The Biospecimen Extraction Resource (BER) is a centralized laboratory for standardized, high-quality, reasonably-priced DMA and RNA extraction from various sources. The BER performs PCR-based analysis of these nucleic acids including pyrosequencing for genotyping of single nucleotide polymorphisms and for detection of CpG island methylation. In addition, the BER consults with non-laboratory-based investigators to help them accomplish their laboratory-based goals related to the facility. The BER is located in the newlyconstructed Basic Science Research Building (BSRB). The BER uses state-of-the-art instrumentation including the Autopure LS automated DMA extraction machine and the PSQ pyrosequencer. The BER has an 8-member oversight committee. A website provides information about services, guidelines for preparing samples for DMA extraction, and other procedures performed by the facility, as well as forms to be completed when requesting service. In the current grant period, the BER was used by 35 different investigators from 17 programs with 98% of usage coming from investigators having peer-reviewed funding. Most of the DMA extractions are from human peripheral blood leukocytes or saliva. An increase of over 400% has been seen over the past year compared to those extracted in 2002. The source of funds for the proposed operating budget of the BER for year 33 (July 1, 2008-June 30, 2009) is 14% from TexGen, 53% from user fees, and 34% from the CCSG. Future plans include continued expansion to large projects such as TexGen, the """"""""LBJ Patient History Database-Serum/DNA Bank"""""""" and the """"""""Repository of Tissue and Blood on Patients in the Cancer Prevention Center.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530387
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311
Andermann, Tessa M; Peled, Jonathan U; Ho, Christine et al. (2018) The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 24:1322-1340
Tiwary, Shweta; Morales, John E; Kwiatkowski, Sam C et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. Sci Rep 8:8267
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 12418 publications